tients with clinical ASCVD and in a smaller number of high-risk primary prevention patients. In addition, further evidence on the types of patients most likely to benefit from the use of ezetimibe in addition to statin therapy after acute coronary syndrome has been published. Based on results from these important analyses, the ECDP writing committee judged that it would be desirable to provide a focused update to help guide clinicians more clearly on decision making regarding the use of ezetimibe and PCSK9 inhibitors in patients with clinical ASCVD with or without comorbidities. In the following summary table, changes from the 2016 ECDP to the 2017 ECDP Focused Update are highlighted, and a brief rationale is provided. The content of the full document has been changed accordingly, with more extensive and detailed guidance regarding decision making provided both in the text and in the updated algorithms. Revised recommendations are provided for patients with clinical ASCVD with or without comorbidities on statin therapy for secondary prevention. The ECDP writing committee judged that these new data did not warrant changes to the decision pathways and algorithms regarding the use of ezetimibe or PCSK9 inhibitors in primary prevention patients with LDL-C <190 mg/dL with or without diabetes mellitus or patients without ASCVD and LDL-C $190 mg/dL not due to secondary causes. Based on feedback and further deliberation, the ECDP writing committee down-graded recommendations regarding bile acid sequestrant use, recommending bile acid sequestrants only as optional secondary agents for consideration in patients intolerant to ezetimibe. For clarification, the writing committee has also included new information on diagnostic categories of heterozygous and homozygous familial hypercholesterolemia, based on clinical criteria with and without genetic testing. Other changes to the original document were kept to a minimum to provide consistent guidance to clinicians, unless there was a compelling reason or new evidence, in which case justification is provided. Table 1 . 
ECDP Algorithms
Thresholds for consideration of net ASCVD risk reduction benefit were percent reduction in LDL-C and may consider absolute LDL-C level in patients with clinical ASCVD, baseline LDL-C $190 mg/dL, and primary prevention. In patients with diabetes with or without clinical ASCVD, it was stated that the clinician may consider absolute LDL-C and/or non-HDL-C levels.
Thresholds for consideration of net ASCVD risk reduction are percent reduction in LDL-C and may consider absolute LDL-C or non-HDL-C levels for patients in each of the 4 statin benefit groups.
Comment/Rationale: The FOURIER trial of evolocumab included patients with clinical ASCVD with or without diabetes on statin dose equivalent of at least atorvastatin 20 mg who had either LDL-C ‡70 mg/dL or non-HDL-C ‡100 mg/dL (2) . The ongoing ODYSSEY Outcomes trial of alirocumab includes patients with non-HDL-C ‡100 mg/dL (4) . The SPIRE-2 trial of bococizumab included high-risk primary prevention patients (18.9%) and patients with familial hypercholesterolemia (7.0%) with LDL-C ‡100 mg/dL or non-HDL-C ‡130 mg/dL (5) . In alignment with these inclusion criteria, the 2017 Focused Update includes both LDL-C and non-HDL-C thresholds for evaluation of net ASCVD risk reduction benefit when considering the addition of non-statin therapies for patients in each of the 4 statin benefit groups. Thresholds for consideration of net ASCVD risk reduction benefit in patients with clinical ASCVD without comorbidities were $50% reduction in LDL-C and may consider LDL-C <100 mg/dL. Thresholds for patients with clinical ASCVD with comorbidities were $50% reduction in LDL-C and may consider LDL-C <70 mg/dL.
Thresholds for consideration of net ASCVD risk-reduction benefit are LDL-C reduction $50% and may consider LDL-C <70 mg/dL or non-HDL-C <100 mg/dL for all patients with clinical ASCVD and baseline LDL-C 70-189 mg/dL.
Comment/Rationale: The writing committee considered the results of the cardiovascular outcomes trials, IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) and FOURIER, demonstrating the safety and efficacy of the addition of ezetimibe or evolocumab to maximally tolerated statin therapy in patients with clinical ASCVD and on-statin-treatment LDL-C levels of approximately 70 mg/dL in IMPROVE-IT and 92 mg/dL in FOURIER (2, 6) . Based on consideration of all available evidence, the consensus of the writing committee members is that lower LDL-C levels are safe and optimal in patients with clinical ASCVD due to the increased risk of recurrent events. If a decision is made to proceed with the addition of nonstatin therapy to maximally tolerated statin therapy, it is reasonable to consider the addition of ezetimibe as the initial agent and a PCSK9 inhibitor as the second agent.
If a decision is made to proceed with the addition of nonstatin therapy to maximally tolerated statin therapy in patients with clinical ASCVD with comorbidities and baseline LDL-C 70-189 mg/dL, it is reasonable to consider the addition of either ezetimibe or a PCSK9 inhibitor based on considerations of the additional percent LDL-C reduction desired, patient preferences, costs, route of administration, and other factors. Clinicians should preferentially prescribe drugs that have been shown in RCTs to provide ASCVD risk-reduction benefits that outweigh the potential for adverse effects and drug-drug interactions, and consider patient preferences. Considerations that may favor the initial choice of ezetimibe include: patients who require <25% additional lowering of LDL-C, patients with recent ACS <3 months, cost considerations with recent availability of generic ezetimibe and future cost savings, ease of use as oral agent with low pill burden, patient preferences, heart failure, hypertension, age >75 years, diabetes, stroke, CABG, PAD, eGFR <60 ml/min/1.73 m 2 , and smoking. If patients with clinical ASCVD and comorbidities require >25% additional lowering of LDL-C, a PCSK9 inhibitor may be preferred as the initial non-statin agent. The clinician-patient discussion should consider the extent of available scientific evidence for net ASCVD risk-reduction benefit, cost, administration by subcutaneous injection, every 14-day or monthly dosing schedule, and storage requirements (refrigeration). (7) . The magnitude of risk reduction in cardiovascular death, MI, or stroke appeared to increase over time, from 16% in the first year of follow-up to 25% beyond 1 year. See text for further details. The ongoing ODYSSEY Outcomes trial includes 18,600 post-ACS (4-52 weeks) patients on evidence-based statin therapy who are randomized to the addition of alirocumab or placebo. The primary endpoint is CHD death, MI, ischemic stroke, or hospitalization for unstable angina. The estimated study completion date is December 2017 (4) . A recent post-hoc analysis of IMPROVE-IT identified 9 clinical variables (congestive heart failure, hypertension, age >75 years, diabetes, stroke, CABG, PAD, eGFR <60 ml/min/1.73 m 2 , and smoking) that may help predict patients after ACS who have the greatest likelihood of benefit from the addition of ezetimibe to statin therapy following ACS (8). greater ASCVD risk reduction with minimal serious adverse event rates, typically similar to the adverse event rates in placebo comparator groups (14) . Of note, the 2013 ACC/AHA guideline panel emphasized the role of shared decision making between clinicians and patients, with consideration of net benefit as well as patient preferences, especially in the setting of primary prevention, in which the marginal benefits may be small for patients at lower risk for ASCVD events in the near term (9) . (7) . The inclusion criteria in FOURIER were clinical ASCVD and at least 1 major risk factor (patients with age ‡65 years, prior MI or non-hemorrhagic stroke, current daily cigarette smoking, symptomatic PAD with prior MI or stroke) or 2 minor risk factors (history of non-MI related coronary revascularization, residual coronary artery disease with ‡40% stenosis in ‡2 large vessels, HDL-C <40 mg/dL for men and <50 mg/dL for women, hs-CRP >2 mg/L, or metabolic syndrome).
therapy, patients on average had $50% reduction in LDL-C from baseline. In trials showing efficacy of moderateintensity statin therapy, patients typically had on average 30% to <50% reduction in LDL-C from baseline. These levels of therapeutic response were therefore taken to indicate adequate response and adherence to therapy.
Because no large RCTs have evaluated the outcome of drug titration to specific LDL-C targets, the 2013 ACC/AHA cholesterol guideline panel did not make specific recommendations regarding lipoprotein goals of therapy.
Instead, the panel recommended initiating either high-or moderate-intensity statin therapy on the basis of patient ASCVD risk characteristics and the potential for net benefit; however, the panel did note that groups of patients with the greatest benefit from statin therapy tended to fall into ranges of LDL-C indicating efficacy of statin therapy. For example, the guideline panel indicated that "in those already on a statin, in whom baseline LDL-C is unknown, an LDL-C level <100 mg/dL was observed in most individuals receiving high-intensity statin therapy" (9) . This statement was based on the findings from trials such as Treating to New Targets, in which patients with clinical coronary heart disease were randomized to fixeddose atorvastatin 80 mg versus 10 mg daily as an active comparator (15) . The patients receiving 80 mg of atorvastatin achieved a mean LDL-C of 77 mg/dL, with the majority achieving <100 mg/dL, whereas the patients receiving 10 mg of atorvastatin achieved a mean LDL-C of 101 mg/dL. This difference was associated with a significant 22% reduction in major cardiovascular events in the trial.
In summary, the 2013 ACC/AHA cholesterol guideline panel recommended using either high-or moderateintensity statin therapy for patients in the 4 statin benefit groups at risk for ASCVD in primary and sec- During the conduct of the SPIRE-1 and -2 cardiovascular outcomes trials, data from the SPIRE lipid-lowering trials became available, indicating that the common development of high-titer antidrug antibodies, of which the majority were neutralizing antibodies, resulted in significant attenuation of LDL-C lowering over time (19) . In addition, Table 1 .
METHODS

Background
In 2013, the ACC launched "LDL: 
2017 Focused Update of LDL ECD Pathway -, 2017:---non-statin therapies into treatment strategies for higherrisk patients as a critical gap in clinical care.
Process
The guidance that follows in this document was informed by the scientific evidence presented and expert opinions considered during the Think Tank Non-statin therapies: Currently available strategies and agents that are considered in this document for the management of LDL-related ASCVD risk are described in Table 4 . Dietary adjuncts for lowering atherogenic cholesterol may also be considered for patients with dyslipidemia, including phytosterols and soluble dietary fibers (21). As outlined in Table 4 , there are important considerations in the choice of non-statin pharmacological agents that may make a treatment modality preferable in specific patient populations (e.g., pregnant women, elderly patients, patients with diabetes). These considerations include the extent of available scientific evidence for net ASCVD risk-reduction benefit, safety and tolerability, potential for drug-drug interactions, efficacy of additional LDL-C lowering, cost, convenience and medication storage, pill burden, route of administration, potential to jeopardize adherence to evidence-based therapies, and importantly, patient preferences. Before initiation of combination therapy, it is imperative for clinicians and patients to engage in a discussion that addresses the potential for net benefit, including absolute ASCVD risk-reduction benefits and potential harms, prescribing considerations, and patient preferences for treatment ( Table 5 ) (9).
The expert consensus writing committee undertook an iterative process to determine the higher-risk patient groups that should be considered for additional LDL-C lowering therapies, the appropriate strategies that should be considered for each group, and the order in which those strategies should be considered. The committee first considered a base case of a patient without significant comorbidities within each of the 4 statin benefit groups. The appropriate strategies and the order of consideration were first determined for these patients.
Once the committee reached consensus on this scenario, members undertook an iterative process of discussion and consideration of special circumstances for subpopulations with comorbidities, and then updated the strategies in order to create a clinical pathway, or algorithm, that could be followed by clinicians for each patient scenario. All issues were discussed and all pathways were finalized with full consensus of the committee members.
Of note, the writing committee did not consider therapies for severe hypertriglyceridemia (prescription omega-3 fatty acids, fibric acid derivatives), which have been addressed elsewhere recently (26, 27) . On the basis of currently available evidence of non-efficacy and potential harms, the committee judged that there are no clear indications for the routine use of niacin preparations as additional non-statin therapies, and niacin is not recommended for use in any of the clinical situations addressed below (28) .
A bile acid sequestrant (BAS) may be considered as an optional alternative agent for those with ezetimibe intolerance and with triglycerides <300 mg/dL or due to patient preference, but there is no evidence for net cardiovascular risk reduction benefit of BAS in addition to statins (29) . The BAS are, therefore, noted only as an option in the footnotes of the following algorithms.
Special populations not included in 1 of the 4 statin benefit groups (patients with heart failure, patients on maintenance hemodialysis, and women considering pregnancy or already pregnant) are considered in a separate section below.
ASSUMPTIONS AND DEFINITIONS
To limit inconsistencies in interpretation, specific assumptions and definitions were considered by the writing committee in the development of this document.
1. The expert consensus writing committee endorses the evidence-based approaches to ASCVD risk reduction in adults enumerated in the 2013 ACC/AHA Guideline on 3. These algorithms assume that the patient is currently taking or has attempted to take a statin, as a result of shared decision making, and that the clinician and patient are trying to determine whether additional therapy is needed to reduce ASCVD risk further.
4. These algorithms were crafted based on the principle of potential net ASCVD risk-reduction benefit, meaning that the potential benefits of additional non-statin therapy should outweigh any potential for harm.
Other considerations include the extent of available scientific evidence for safety and tolerability, potential for drug-drug interactions, efficacy of additional LDL-C lowering, cost, convenience and medication storage, pill burden, route of administration, potential to jeopardize adherence to evidence-based therapies, and importantly, patient preferences. Before initiation of combination therapy, it is imperative for clinicians and patients to engage in a discussion that addresses the potential for net benefit, including absolute ASCVD risk-reduction benefits and potential harms, prescribing considerations, and patient preferences for treatment ( Table 5) .
5. Critical to the decision-making process for use of additional non-statin therapies in select high-risk patients was the definition of the concept of thresholds for consideration of net ASCVD risk-reduction benefit.
The expert consensus writing committee endorsed the evidence-based findings from the 2013 ACC/AHA cholesterol guideline regarding the use of appropriate intensity statin therapy and the indicators of efficacy (e.g., $50% LDL-C reduction for high-intensity statin doses and 30% to <50% reduction for moderateintensity doses). In addition, the committee acknowledged that patients in the RCTs demonstrating efficacy and safety of LDL-C lowering therapy tended to achieve absolute LDL-C levels within a given range.
Therefore, assuming adherence to therapy, patients with LDL-C levels above that range may not achieve maximal benefit and might be considered for additional therapy. The committee, therefore, judged that it was appropriate to provide levels of LDL-C, or 
Lloyd-Jones et al. Lloyd-Jones et al. As noted, if moderate-intensity statins are employed, the objective is to achieve a 30% to <50% reduction of LDL-C, and for high-intensity statins, $50% LDL-C reduction.
As per the 2013 ACC/AHA guideline, fewer people >75 years of age were enrolled in the statin RCTs, but avail- consider LDL-C <70 mg/dL or non-HDL-C <100 mg/dL), it is reasonable to continue current therapy and continue to monitor adherence to medications and lifestyle, and ongoing LDL-C response to therapy.
If, after these interventions, the patient still has <50% reduction in LDL-C (and may consider LDL-C $70 mg/dL or non-HDL-C $100 mg/dL), the patient and clinician should enter into a discussion focused on shared decision making regarding the addition of a non-statin medication to the current regimen. The clinician-patient discussion is described in Table 5 and should address: the potential for additional ASCVD risk reduction that could be expected from the addition of a non-statin therapy to lower LDL-C further; the potential for adverse events or drug-drug interactions from addition of non-statin therapy ( Table 4) ;
and patient preferences, including considerations of the patient's perception of net benefit, convenience/burden of additional therapy, cost, quality of life, and the potential to jeopardize adherence to other evidence-based therapies. If a decision is made to pursue no additional medication at this point, it is reasonable to continue current therapy and continue to monitor adherence to medications and lifestyle, and ongoing LDL-C response to therapy.
Although there is a gap in RCT evidence demonstrating outcomes benefits of using ezetimibe plus statin therapy in stable clinical ASCVD patients, the writing committee supports consideration of adding ezetimibe 10 mg daily as
Lloyd-Jones et al. If, after these interventions, the patient still has <50% reduction in LDL-C (and may consider LDL-C $70 mg/dL or non-HDL-C $100 mg/dL), the patient and clinician should enter into a discussion focused on shared decision making regarding the addition of a non-statin medication to the current regimen. The clinician-patient discussion is described in Table 5 and should address: the potential for additional ASCVD risk reduction that could be expected from the addition of a non-statin therapy to lower LDL-C further; the potential for adverse events or drug-drug interactions from addition of non-statin therapy ( Table 4) If, after these interventions, the patient still has <50% reduction in LDL-C (and may consider LDL-C $70 mg/dL or non-HDL-C $100 mg/dL), the patient and clinician
Lloyd-Jones et al. ( Table 4 ) (2,6).
Although there is a gap in RCT evidence demonstrating outcomes benefits of using ezetimibe plus statin therapy 
Lloyd-Jones et al. If, after these interventions, the patient still has <50% reduction in LDL-C (and may consider LDL-C $100 mg/dL or non-HDL-C $130 mg/dL), the patient and clinician should enter into a discussion focused on shared decision making regarding the addition of a nonstatin medication to the current regimen ( Table 5) .
Consideration may be given to either ezetimibe or a 
If escalation to high-intensity statin results in <50%
reduction in LDL-C (and may consider LDL-C $100 mg/dL or non-HDL-C $130 mg/dL), the clinician and patient
2017 Focused Update of LDL ECD Pathway -, 2017:---should enter into a discussion focused on shared decision making regarding the addition of a non-statin medication to the current regimen ( Table 5) . If a decision is made to pursue no additional medication at this point, it is reasonable to continue current therapy and continue to monitor adherence to medications and lifestyle, and ongoing LDL-C response to therapy.
In patients with diabetes and <7.5% In addition to intensive lifestyle modifications, the addition of soluble dietary fiber and phytosterols may also be incorporated in primary prevention patients with diabetes prior to consideration of combination therapy with a non-statin agent.
In higher-risk patients with diabetes who achieve inadequate lowering of LDL-C or non-HDL-C with highintensity statin therapy, the potential net ASCVD riskreduction benefit of combination therapy may be considered for patients with <50% reduction in LDL-C (and may consider LDL-C $100 mg/dL or non-HDL-C $130 mg/dL).
Although there is a gap in RCT evidence demonstrating outcomes benefits of using ezetimibe plus statin in primary prevention patients with diabetes, the writing committee supports that ezetimibe 10 mg daily may be considered as the initial non-statin agent for most patients in whom additional LDL-C lowering is desired. Ezetimibe is preferred as the initial non-statin therapy due to its tolerability, convenience, and single-tablet daily dose. BAS have a modest hypoglycemic effect that may be of benefit in some diabetic patients with fasting triglycerides <300 mg/dL. BAS may be considered in patients who have an inadequate response to ezetimibe or are ezetimibe intolerant. Of note, the writing committee did not consider therapies (prescription omega-3 fatty acids, fibric acid derivatives) for severe hypertriglyceridemia, which is common in patients with diabetes, since this topic has been addressed elsewhere recently (26, 27) . Failure) and GISSI-HF (Gruppo Italiano per lo Studio della
Lloyd-Jones et al. -, 2017:--- 2017 Focused Update of LDL ECD Pathway Sopravvivenza nell'Infarto Miocardico Heart Failure) trials directly addressed the use of statins in patients with symptomatic heart failure and reduced left ventricular ejection fraction (42, 43) . The CORONA trial randomized 5,011 patients aged 60 years or older with ischemic etiology of heart failure and an ejection fraction #40% and New York Heart Association (NYHA) functional class II to IV symptoms to 10 mg of rosuvastatin versus placebo (42, 44) . The GISSI-HF trial randomized 4,574 patients aged $18 years with heart failure of ischemic and nonischemic etiology with ejection fraction #40% (or >40%
if hospitalized within the past year) also to 10 mg of rosuvastatin versus placebo (44) . Neither the CORONA nor the GISSI-HF trial demonstrated significant reductions in primary endpoints or major secondary endpoints. Both trials were notable for the very high all-cause mortality rates experienced by study participants regardless of randomization status, suggesting very high competing risks; however, a recent individual-level pooled data meta-analysis of these trials, which also accounted for the competing risks of mortality, demonstrated a significant 19% reduction in MI rates among patients with ischemic etiology of heart failure (45) . Thus, the expert consensus writing committee judges that it is reasonable to consider use of statins in patients with symptomatic heart failure due to ischemic etiology who, in the clinician's judgment, have reasonable expectation of surviving long enough to achieve benefit from the statin therapy (i.e., 3 to 5 years or more). No data exist examining the use of non-statin therapies in heart failure patients, and heart failure is an exclusion criterion in recent PCSK9 inhibitor trials.
In light of the aforementioned considerations, the approach to patients with ASCVD and NYHA functional class II to III heart failure due to ischemic heart disease should generally follow the algorithm for patients with ASCVD and comorbidities, with the exception that use of a PCSK9 inhibitor is not recommended at this time Referral to lipid specialist n Consider referring patients with baseline LDL-C $190 mg/dL, very high risk for ASCVD, complex lipid disorders, statin intolerance or multiple lipid medication intolerances, or familial hypercholesterolemia for consultation with a lipid specialist for advanced management. n Considerations in referring: Lipid specialists may not be easily available in some rural or remote locations.
Ezetimibe (49) n Mechanism of action: Inhibits Niemann-Pick C1 like 1 (NPC1L1) protein; reduces cholesterol absorption in small intestine. n FDA-approved indication(s): As adjunct to diet to: 1) Y TC, LDL-C, Apo B, non-HDL-C in patients with primary hyperlipidemia, alone or in combination with a statin; 2) Y TC, LDL-C, Apo B, non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate; 3) Y TC, LDL-C with HoFH, in combination with atorvastatin or simvastatin; 4) Y sitosterol and campesterol in patients with homozygous sitosterolemia (phytosterolemia). n Dose: 10 mg PO daily, with or without food. Take either $2 hours before or $4 hours after BAS if used in combination. n Mean % reduction in LDL-C (per PI): Monotherapy-18%; combination therapy with statin (incremental reduction)-25% n Adverse effects: Monotherapy-upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity; combination with statin-nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, diarrhea. n Drug-drug interactions: cyclosporine, fibrates, BAS n CV outcomes trials: IMPROVE-IT (6) (The addition of ezetimibe to moderate-intensity statin in patients with recent ACS resulted in incremental lowering of LDL-C and reduced primary composite endpoint of CV death, nonfatal MI, UA requiring re-hospitalization, coronary revascularization [$30 days after randomization], or nonfatal stroke. The median follow-up was 6 years.); SHARP (46) (Simvastatin plus ezetimibe reduced LDL-C and reduced primary endpoint of first major ASCVD event [nonfatal MI or CHD death, non-hemorrhagic stroke, or any arterial revascularization procedure] compared to placebo over a median f/u of 4.9 years). n Prescribing considerations: Generally well tolerated. Generic available. (50, 51) (7, 52) . n Drug-drug interactions: No clinically significant drug-drug interactions identified for alirocumab or evolocumab. n CV outcomes trials: Alirocumab-ODYSSEY Outcomes (4) (18,600 post-ACS [4-52 weeks] patients on evidence-based statin therapy; Primary endpoint is CHD death, MI, ischemic stroke, or hospitalization for UA. Estimated study completion is December 2017). Evolocumab-FOURIER (7) (27,564 patients with prior MI, stroke, or PAD on atorvastatin $20 mg or equivalent; Demonstrated that addition of evolocumab reduced the primary endpoint of CV death, MI, stroke, revascularization or hospi talization for UA). Bococizumab-SPIRE-1 and -2 (2) (27,438 patients at high risk of CV event with LDL-C 70-99 mg/dL or $100 mg/dL [SPIRE-2] on lipid-lowering therapy; Studies terminated by sponsor at median follow-up 10 months). There was no benefit in the combined analysis with respect to the primary composite endpoint of CV death, MI, stroke, or urgent revascularization. n Considerations in prescribing: Cost, SQ administration, robust LDL-C reduction, CV outcomes trials not completed for alirocumab, burdensome prior authorization process
PCSK9 inhibitors
Continued
Strategy/Agent Comments
Bile acid sequestrants (53) (54) (55) (56) n Mechanism of action: Non-absorbed, lipid-lowering polymer that binds bile acids in intestine and impedes their reabsorption. As the bile acid pool Y, the hepatic enzyme, cholesterol 7-a-hydroxylase, is upregulated, which [ conversion of cholesterol to bile acids. This causes [ demand for cholesterol in the liver cells, resulting in the dual effect of increasing transcription and activity of the cholesterol biosynthetic enzyme, HMG-CoA reductase, and [ the number of hepatic LDL receptors. These compensatory effects result in [ clearance of LDL-C from the blood, in turn resulting in Y serum LDL-C levels. Serum TG levels may [ or remain unchanged. n FDA-approved indication(s): Colesevelam: 1) Adults, as adjunct to diet and exercise, to Y LDL-C with primary hyperlipidemia: monotherapy or in combination with statin; 2) Adults, as adjunct to diet and exercise, to improve glycemic control with type 2 diabetes mellitus; 3) Boys and post-menarchal girls, 10 to 17 years of age, with HeFH after failing an adequate trial of diet therapy (e.g., LDL-C remains $190 mg/dL; or LDL-C remains $ 160 mg/dL and there is a positive family history of premature CVD or $2 other CVD risk factors are present in the pediatric patient) to Y LDL-C levels: As monotherapy or in combination with statin. Cholestyramine, colestid: As adjunct to diet to Y LDL-C with primary hyperlipidemia. n Dose and route of administration: 1) Colesevelam: Tablets: 6 tablets PO once daily or 3 tablets PO twice daily; take tablets with a meal and liquid. Suspension: one 3.75-gram packet PO daily, or one 1.875-gram packet PO twice daily; mixed powder with 4-8 ounces of water, fruit juice, or soft drink; take with meal. 3.75 g is equivalent to 6 tablets. 1.875 g is equivalent to 3 tablets; 2) Cholestyramine: 8-16 g/day orally divided into 2 doses; 3) Colestipol: 2-16 g/day orally given once or in divided doses. n Mean % LDL reduction (per PI): Colesevelam: Monotherapy-15% (6 tablets daily); combination with low-to moderate-intensity statin-additional 10% to 16% reduction in LDL-C (data from simvastatin 10 mg, atorvastatin 10 mg). Cholestyramine: Monotherapy-10.4% vs placebo. Colestipol: not provided in PI. In dose-ranging RCT with monotherapy, doses of 5 g, 10 g, and 15 g resulted in 16.3%, 22.8%, and 27.2% reduction in LDL-C, respectively (57) n Adverse effects: Constipation, dyspepsia, and nausea. Post-marketing reports with colesevelam include [ seizure activity or Y phenytoin levels in patients receiving phenytoin, Y INR in patients receiving warfarin, [ TSH in patients receiving thyroid hormone replacement therapy, bowel obstruction, dysphagia, esophageal obstruction, fecal impaction, hypertriglyceridemia, pancreatitis, and increased transaminases n Drug-drug interactions: Drugs with potential interaction should be taken at least 1 hour before or 4 hours after BAS to avoid impeding their absorption. n CV outcomes trials: LRC-CPPT (3,806 asymptomatic middle-aged men with primary hypercholesterolemia randomized to cholestyramine resin and versus placebo for an average of 7.4 years). Cholestyramine group experienced a 19% reduction in risk (p < 0.05) of the primary endpoint-definite CHD death and/or definite nonfatal MI. The effects of colesevelam and colestipol on cardiovascular morbidity and mortality have not been determined. n Considerations in prescribing: Pill burden; inconvenience in preparation of oral suspension preparations; GI side effects; exacerbation of hypertriglyceridemia; orally administered, colesevelam lowers HbA1c 0.5% in diabetes; CV outcomes data not available.
Phytosterols n Mechanism of action: Not fully elucidated, but in part related to displacement of cholesterol from the micellar phase. Phytosterols Y cholesterol content of micelles and hence Y its transport towards the intestinal brush border membrane. May also interfere with transporter-mediated processes of cholesterol uptake via NPC1L1 protein and ABCG5 and ABCG8 transporters. n FDA-approved claims: "For plant sterol esters: (i) Foods containing at least 0.65 g per serving of plant sterol esters, eaten twice a day with meals for a daily total intake of at least 1.3 g, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease. For plant stanol esters: (i) Foods containing at least 1.7 g per serving of plant stanol esters, eaten twice a day with meals for a total daily intake of at least 3.4 g, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease." n Dose and route of administration: 1-3 g PO per day consumed with meals either once daily or in divided doses. n Mean % LDL-C reduction: Consumption of 2 g/day of phytosterols Y LDL-C by 5%-15%. LDL-C Y plateaus at doses above w3 g/day. n Adverse effects: Phytosterol esters have "generally recognized as safe" (GRAS) status in the U.S. Potential safety concern regarding phytosterol consumption in patients with phytosterolemia. Side effects may include mild bloating, diarrhea, or constipation. n Drug-drug interactions: BAS administration should be separated from phytosterol use by 2-4 hours to avoid binding of the latter in the gut. n CV outcomes trials: The effect of phytosterols on cardiovascular morbidity and mortality as not been determined. n Considerations in prescribing: Generally well tolerated; modest Y in LDL-C; CV outcomes data not available.
Soluble/viscous fiber n Mechanism of action: Trapping of cholesterol and bile acids in the small intestine, resulting in Y absorption/reabsorption. n FDA-approved claims: "Soluble fiber as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease." n Dose and route of administration: Food source must be low in saturated fat and cholesterol, and include 1 or more of the following whole oat or barley foods: 1) oat bran, 2) rolled oats, 3) whole oat flour, 4) whole grain barley or dry milled barley. n Mean % LDL-D reduction: With intake of 3.0-12.4 g/day, mean TC and LDL-C levels were Yrelative to control by 9.7 and 11.6 mg/dL, respectively. n Adverse effects: Few safety concerns. If viscous fiber supplements such as fiber laxatives are used, it is critical to consume adequate fluid as directed on the product label to avoid intestinal blockage (a rare occurrence). n Drug-drug interactions: Reduced carotenoid absorption. Regular consumption of fruits and vegetables should help to counteract this potential effect. n CV outcomes trials: Despite evidence of LDL-C lowering, the effect of soluble/viscous fiber on cardiovascular morbidity and mortality has not been demonstrated in RCTs. n Considerations in prescribing: GI tolerability As an adjunct to lipid-lowering medications and diet, YLDL-C, apo B, TC, and non-HDL-C in patients with HoFH. The safety and effectiveness of mipomersen have not been established in patients with hypercholesterolemia who do not have HoFH. The use of mipomersen as an adjunct to LDL apheresis is not recommended. n Dose and route of administration: 200 mg SQ once weekly n Mean % LDL-C reduction (per PI): Response to addition of mipomersen to maximally tolerated lipid-lowering medication in patients with HoFH-25%. n Adverse effects: Injection site reactions, flu-like symptoms, nausea, headache and elevations in serum transaminases, specifically ALT. Increases hepatic fat (hepatic steatosis) with or without concomitant increases in transaminases. May be a risk factor for progressive liver disease, including steatohepatitis and cirrhosis. Because of the risk of hepatotoxicity, mipomersen is available only through REMS program. n Drug-drug interactions: No clinically relevant pharmacokinetic interactions were reported between mipomersen and warfarin, simvastatin, or ezetimibe. n CV outcomes trials: The effect of mipomersen on cardiovascular morbidity and mortality has not been determined. n Considerations in prescribing: Cost, SQ administration, requires monitoring of transaminase levels, long-term consequences of hepatic steatosis unknown, prescriber training, REMS program
Lomitapide (59) n Mechanism of action: Directly binds and inhibits microsomal triglyceride transfer protein (MTP), which resides in the lumen of the endoplasmic reticulum, thereby preventing the assembly of apo B-containing lipoproteins in enterocytes and hepatocytes. This inhibits the synthesis of chylomicrons and VLDL and leads to Y LDL-C. n FDA-approved indications: As an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to Y LDL-C, TC, apo B, and non-HDL-C in patients with HoFH. n Dose and route of administration: Initiate 5 mg PO once daily. Titrate dose based on acceptable safety/tolerability: increase to 10 mg daily after at least 2 weeks and then, at a minimum of 4-week intervals, to 20 mg, 40 mg, and up to maximum recommended dose of 60 mg daily. n Mean % LDL reduction (per PI): Mean and median percent changes in LDL-C from baseline when added to baseline lipid-lowering therapy were À40% and À50%, respectively. n Adverse effects: Diarrhea, nausea, vomiting, dyspepsia, and abdominal pain. Increases hepatic fat (hepatic steatosis) with or without concomitant increases in transaminases. Hepatic steatosis associated with lomitapide may be a risk factor for progressive liver disease, including steatohepatitis and cirrhosis. n Drug-drug interactions: CYP3A4 inhibitors increase exposure to lomitapide. Strong and moderate CYP3A4 inhibitors are contraindicated with lomitapide. Avoid grapefruit juice. Do not exceed 30 mg daily of lomitapide when used concomitantly with weak CYP3A4 inhibitors, including atorvastatin and oral contraceptives. Increases plasma concentrations of warfarin; monitor INR regularly, especially with lomitapide dose adjustment. Increased systemic exposure to simvastatin and lovastatin exposure with lomitapide. Limit statin dose when co-administered due to myopathy risk. Consider dose reduction of P-gp substrate because of possible increased absorption with lomitapide. Separate lomitapide dosing with BAS by at least 4 hours. Because of the risk of hepatotoxicity, lomitapide available only through REMS program. n CV outcomes trials: The effect of lomitapide on cardiovascular morbidity and mortality has not been determined. n Considerations in prescribing: Cost, oral administration, requires strict adherence to low-fat diet and gradual dose escalation to reduce GI side effects, requires monitoring of transaminase levels, long-term consequences of hepatic steatosis unknown, prescriber training, REMS program LDL apheresis n Mechanism of action: Selectively removes apo B-containing lipoproteins, producing an acute reduction in LDL-C. n FDA approved indication: Patients with FH unresponsive to pharmacologic and dietary management who are either functional homozygotes with a LDL-C >500 mg/dL, functional heterozygotes with no known cardiovascular disease but a LDL-C >300 mg/dL, or functional heterozygotes with known cardiovascular disease and LDL-C >200 mg/dL. n Dose and route of administration: Extracorporeal technique performed weekly or biweekly. n Mean % LDL-C reduction: With weekly or biweekly treatment, average LDL-C can Y to w50%-60% of the original levels. LDL-C increases after each apheresis session but does not return to the original level. n Adverse effects: Problems with venous access; transient hypotension, fatigue; bleeding; hypocalcemia; iron deficiency due to regular phlebotomy for diagnostic purposes; heparin allergy; and bradykinin syndrome (especially with ACEI). n Drug-drug interactions: ACEI should not be used with dextran sulfate method owing to risk of bradykinin syndrome. n CV outcomes trials: Limited due to ethical considerations in RCTs of very high-risk patients with HoFH, but it is reasonable to assume reductions in CVD events are proportional to the degree of LDL cholesterol lowering. n Considerations in prescribing: Cost, extracorporeal technique, inconvenient, locations not readily available in some regions, time-consuming, robust reduction in LDL-C.
ASCVD indicates atherosclerotic cardiovascular disease; BAS, bile acid sequestrant; CHD, coronary heart disease; CV, cardiovascular; GI, gastrointestinal; HDL-C, high-density lipoprotein cholesterol; HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; INR, international normalized ratio; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; PAD, peripheral arterial disease; PCSK9, proprotein convertase subtilisin/kexin 9; PI, prescribing information; PO, by mouth; REMS, Risk Evaluation and Mitigation Strategy; SQ, subcutaneous; TC, total cholesterol; TG, triglycerides; TSH, thyroid stimulating hormone; UA, unstable angina; and VLDL, very low density lipoprotein.
TA BLE 5
Factors to Consider in the Clinician-Patient Discussion 1. Potential for additional ASCVD risk reduction from addition of non-statin therapy to evidence-based statin therapy to lower LDL-cholesterol n Percentage LDL-C reduction achieved with evidence-based statin therapy (if <50% and not on maximally tolerated statin, should increase statin first and reinforce lifestyle modifications) n For patients with ASCVD, patient's baseline ASCVD risk on evidence-based statin therapy (with or without comorbidities)* n For patients without ASCVD or baseline LDL-C $190 mg/dL, patient's baseline predicted 10-year ASCVD risk pre-statin and presence of high-risk markers † n Available scientific evidence of ASCVD risk reduction (and magnitude of benefit) when non-statin therapy is added to evidence-based statin therapy ‡ n Additional desired % LDL-C lowering beyond that achieved on evidence-based statin therapy § n Mean percentage LDL-C lowering expected with proposed non-statin therapy when added to evidence-based statin therapyk 2. Potential for significant adverse events or drug-drug interactions from addition of non-statin therapy to evidence-based statin therapy for lowering LDL-cholesterol n See Table 3. 3. Patient preferences and considerations n Patient's perception of benefit from addition of non-statin therapy n Convenience (e.g., route and frequency of administration, pill burden, storage) of non-statin therapy n Potential of non-statin therapy to jeopardize adherence to evidence-based therapies n Cost of non-statin therapy n Anticipated life expectancy, comorbidities, and impact of therapy on quality of life *For example, in the Treating to New Targets trial, patients with CHD who received 10 mg of atorvastatin daily had a 5-year event rate of 10.9%, and those who received 80 mg of atorvastatin daily had a 5-year event rate of 8.7%. These numbers (and similar rates from other trials) may inform the number-needed-to-treat. Additional consideration of comorbidities and other poorly controlled or well-controlled risk factors will increase or decrease risk accordingly. Comorbidities are defined as diabetes, a recent (<3 months) ASCVD event, an ASCVD event while already taking a statin, poorly controlled other major ASCVD risk factors, elevated Lp(a), CKD, symptomatic heart failure, maintenance hemodialysis, age $65 years, prior MI or non-hemorrhagic stroke, current daily cigarette smoking, symptomatic PAD, history of non-MI related coronary revascularization, residual coronary artery disease with $40% stenosis in $2 large vessels, HDL-C <40 mg/dL for men and <50 mg/dL for women, hs-CRP >2 mg/L, or metabolic syndrome. †Use the Pooled Cohort Equations to estimate 10-year ASCVD risk. High-risk markers include 10-year ASCVD risk $20%, primary LDL-C $160 mg/dL at baseline; poorly controlled other major ASCVD risk factor(s); family history of premature ASCVD with or without elevated Lp(a); evidence of accelerated subclinical atherosclerosis (e.g., coronary artery calcification); elevated hs-CRP; and other risk-modifying conditions, such as CKD, HIV, and chronic inflammatory disorders. ‡Such evidence exists for ezetimibe from the IMPROVE-IT study, with a 6% relative/2% absolute risk reduction in a composite ASCVD endpoint over 7 years when added to a moderateintensity statin. Short-term data (<18 months) from PCSK9 inhibitors alirocumab and evolocumab suggest more substantial ASCVD risk reduction. Data are lacking for addition of BAS to statins. Niacin preparations have been associated with no benefit and potential for significant harms when added to statin therapy. §For example, patients on maximally tolerated statin with LDL-C of 130 mg/dL may receive more benefit from addition of a non-statin therapy than those with on-statin LDL-C of 80 mg/dL. kFor example, when added to statins, ezetimibe may lower LDL-C an additional 20-25% on average; PCSK9 inhibitors may lower LDL-C an additional 60% on average. For each 40 mg/dL reduction in LDL-C using safe and evidence-based therapies, there appears to be an approximate 20% relative risk reduction in ASCVD. This number, combined with the baseline absolute risk, may inform the number-needed-to-treat.
TABLE 6
Familial Hypercholesterolemia Diagnostic Categories 
